FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898472011> ?p ?o ?g. }

• W2898472011 abstract "This is an updated version of the Cochrane Review previously published in 2013.Most people with epilepsy have a good prognosis and their seizures are well controlled by a single antiepileptic drug, but up to 30% develop drug-resistant epilepsy, especially those with focal seizures. In this review, we summarised the evidence from randomised controlled trials (RCTs) of gabapentin, when used as an add-on treatment for drug-resistant focal epilepsy.To evaluate the efficacy and tolerability of gabapentin when used as an add-on treatment for people with drug-resistant focal epilepsy.For the latest update, we searched the Cochrane Register of Studies (CRS Web, 20 March 2018), which includes the Cochrane Epilepsy Group's Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid, 1946 to 20 March 2018), ClinicalTrials.gov (20 March 2018) and the World Health Organization International Clinical Trials Registry Platform (ICTRP, 20 March 2018). We imposed no language restrictions.Randomised, placebo-controlled, double-blind, add-on trials of gabapentin in people with drug-resistant focal epilepsy. We also included trials using an active drug control group or comparing different doses of gabapentin.For this update, two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the following outcomes: seizure frequency, seizure freedom, treatment withdrawal (any reason) and adverse effects. Primary analyses were intention-to-treat. We also undertook sensitivity best-case and worst-case analyses. We estimated summary risk ratios (RR) for each outcome and evaluated dose-response in regression models.We included 12 trials representing 2607 randomised participants. We combined data from six trials in meta-analyses of 1206 randomised participants. The overall RR for reduction in seizure frequency of 50% or more compared to placebo was 1.89 (95% confidence interval (CI) 1.40 to 2.55; 6 trials, 1206 participants; moderate-quality evidence). Dose regression analysis (for trials in adults) showed increasing efficacy with increasing dose, with 25.3% (19.3 to 32.3) of people responding to gabapentin 1800 mg compared to 9.7% on placebo, a 15.5% increase in response rate (8.5 to 22.5). The RR for treatment withdrawal compared to placebo was 1.05 (95% CI 0.74 to 1.49; 6 trials, 1206 participants; moderate-quality evidence). Adverse effects were significantly associated with gabapentin compared to placebo. RRs were as follows: ataxia 2.01 (99% CI 0.98 to 4.11; 3 studies, 787 participants; low-quality evidence), dizziness 2.43 (99% CI 1.44 to 4.12; 6 studies, 1206 participants; moderate-quality evidence), fatigue 1.95 (99% CI 0.99 to 3.82; 5 studies, 1161 participants; low-quality evidence) and somnolence 1.93 (99% CI 1.22 to 3.06; 6 studies, 1206 participants; moderate-quality evidence). There were no significant differences for the adverse effects of headache (RR 0.79, 99% CI 0.46 to 1.35; 6 studies, 1206 participants; moderate-quality evidence) or nausea (RR 0.95, 99% CI 0.52 to 1.73; 4 trials, 1034 participants; moderate-quality evidence). Overall, the studies were rated at low to unclear risk of bias due to information on each risk of bias domain not being available. We judged the overall quality of evidence (using the GRADE approach) as low to moderate due to potential attrition bias resulting from missing outcome data and imprecise results with wide confidence intervals.Gabapentin has efficacy as an add-on treatment in people with drug-resistant focal epilepsy. However, the trials reviewed were of relatively short duration and provide no evidence for the long-term efficacy of gabapentin beyond a three-month period. The results cannot be extrapolated to monotherapy or to people with other epilepsy types." @default.
• W2898472011 created "2018-11-02" @default.
• W2898472011 creator A5005069325 @default.
• W2898472011 creator A5035795713 @default.
• W2898472011 creator A5078322794 @default.
• W2898472011 creator A5081969377 @default.
• W2898472011 creator A5083538395 @default.
• W2898472011 date "2018-10-24" @default.
• W2898472011 modified "2023-10-18" @default.
• W2898472011 title "Gabapentin add-on treatment for drug-resistant focal epilepsy" @default.
• W2898472011 cites W123037942 @default.
• W2898472011 cites W1533692490 @default.
• W2898472011 cites W1567331660 @default.
• W2898472011 cites W1571442295 @default.
• W2898472011 cites W18984091 @default.
• W2898472011 cites W1934102085 @default.
• W2898472011 cites W1967715258 @default.
• W2898472011 cites W1967986271 @default.
• W2898472011 cites W1968212169 @default.
• W2898472011 cites W1972541793 @default.
• W2898472011 cites W1990080741 @default.
• W2898472011 cites W1995716893 @default.
• W2898472011 cites W2033260576 @default.
• W2898472011 cites W2046323117 @default.
• W2898472011 cites W2046391772 @default.
• W2898472011 cites W2071389662 @default.
• W2898472011 cites W2076993158 @default.
• W2898472011 cites W2083722381 @default.
• W2898472011 cites W2095383648 @default.
• W2898472011 cites W2101871493 @default.
• W2898472011 cites W2116965417 @default.
• W2898472011 cites W2146220626 @default.
• W2898472011 cites W2147244904 @default.
• W2898472011 cites W2274786815 @default.
• W2898472011 cites W2300163045 @default.
• W2898472011 cites W2417629680 @default.
• W2898472011 cites W2516435552 @default.
• W2898472011 cites W2592509339 @default.
• W2898472011 cites W4245528808 @default.
• W2898472011 cites W4247231670 @default.
• W2898472011 cites W4301675111 @default.
• W2898472011 cites W4301861531 @default.
• W2898472011 cites W2111860371 @default.
• W2898472011 doi "https://doi.org/10.1002/14651858.cd001415.pub3" @default.
• W2898472011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8094401" @default.
• W2898472011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33434292" @default.
• W2898472011 hasPublicationYear "2018" @default.
• W2898472011 type Work @default.
• W2898472011 sameAs 2898472011 @default.
• W2898472011 citedByCount "7" @default.
• W2898472011 countsByYear W28984720112019 @default.
• W2898472011 countsByYear W28984720112020 @default.
• W2898472011 countsByYear W28984720112021 @default.
• W2898472011 countsByYear W28984720112022 @default.
• W2898472011 crossrefType "journal-article" @default.
• W2898472011 hasAuthorship W2898472011A5005069325 @default.
• W2898472011 hasAuthorship W2898472011A5035795713 @default.
• W2898472011 hasAuthorship W2898472011A5078322794 @default.
• W2898472011 hasAuthorship W2898472011A5081969377 @default.
• W2898472011 hasAuthorship W2898472011A5083538395 @default.
• W2898472011 hasBestOaLocation W28984720112 @default.
• W2898472011 hasConcept C118552586 @default.
• W2898472011 hasConcept C126322002 @default.
• W2898472011 hasConcept C142724271 @default.
• W2898472011 hasConcept C168563851 @default.
• W2898472011 hasConcept C197934379 @default.
• W2898472011 hasConcept C204787440 @default.
• W2898472011 hasConcept C27081682 @default.
• W2898472011 hasConcept C2776608144 @default.
• W2898472011 hasConcept C2778186239 @default.
• W2898472011 hasConcept C2778375690 @default.
• W2898472011 hasConcept C535046627 @default.
• W2898472011 hasConcept C71924100 @default.
• W2898472011 hasConcept C95190672 @default.
• W2898472011 hasConceptScore W2898472011C118552586 @default.
• W2898472011 hasConceptScore W2898472011C126322002 @default.
• W2898472011 hasConceptScore W2898472011C142724271 @default.
• W2898472011 hasConceptScore W2898472011C168563851 @default.
• W2898472011 hasConceptScore W2898472011C197934379 @default.
• W2898472011 hasConceptScore W2898472011C204787440 @default.
• W2898472011 hasConceptScore W2898472011C27081682 @default.
• W2898472011 hasConceptScore W2898472011C2776608144 @default.
• W2898472011 hasConceptScore W2898472011C2778186239 @default.
• W2898472011 hasConceptScore W2898472011C2778375690 @default.
• W2898472011 hasConceptScore W2898472011C535046627 @default.
• W2898472011 hasConceptScore W2898472011C71924100 @default.
• W2898472011 hasConceptScore W2898472011C95190672 @default.
• W2898472011 hasLocation W28984720111 @default.
• W2898472011 hasLocation W28984720112 @default.
• W2898472011 hasLocation W28984720113 @default.
• W2898472011 hasLocation W28984720114 @default.
• W2898472011 hasOpenAccess W2898472011 @default.
• W2898472011 hasPrimaryLocation W28984720111 @default.
• W2898472011 hasRelatedWork W1966047811 @default.
• W2898472011 hasRelatedWork W1983829988 @default.
• W2898472011 hasRelatedWork W1990354178 @default.
• W2898472011 hasRelatedWork W1999346159 @default.
• W2898472011 hasRelatedWork W2003042623 @default.
• W2898472011 hasRelatedWork W202460821 @default.
• W2898472011 hasRelatedWork W2030348591 @default.

• next